Royal Decoration for Erik Frijlink
Professor Henderik Willem Frijlink was nominated by the University of Groningen to receive a royal decoration on Friday 26 April. He was appointed Knight in the Order of the Dutch Lion. He received the accompanying decoration from Marcel Thijssen, Mayor of Tynaarlo.

A royal decoration for inspiring Professor Frijlink
Erik Frijlink (Meppel, 1960) is Professor of Pharmaceutical Technology and Biopharmacy and chair of the research group bearing the same name at the Faculty of Science & Engineering of the UG. After spending six years in the pharmaceutical industry, he started working as a Professor of Pharmaceutical Technology and Biopharmacy 25 years ago.
Together with his research group, he has managed to set up highly successful research projects in both academic and industrial fields. For instance, hundreds of thousands of patients worldwide are grateful to benefit from the applications resulting from his research into powder technology, biopharmaceuticals, and dosage forms.
Colleagues both in the Netherlands and abroad applaud his enthusiasm, warm personality, and collegial attitude, while students fondly recall his enthusiastic, dazzling lectures. He is also known as an academic innovator and is regarded as the perfect example of an academic entrepreneur.
Last modified: | 01 August 2024 3.30 p.m. |
More news
-
07 July 2025
Master’s student Industrial Engineering and Management Ana Lazar wins GUF 100 Prize
At the UG Ceremony of Merits on July 4, Ana Lazar was awarded the GUF 100 Prize, making her the best student of the Faculty of Science and Engineering 2024-2025.
-
03 July 2025
Erik Heeres receives RUG Impact Innovator Excellence Award
During the RUG Ventures Innovation Day, Prof. Erik Heeres of the Faculty of Science and Engineering (RUG) was awarded the Impact Innovator Excellence Award.
-
02 July 2025
€ 30 million investment for UG spin-off Portal Biotech
Portal Biotech, a pioneer in nanopore-based protein identification and sequencing technology, has raised € 30 million in Series A funding. The funding will support commercial rollout and team growth.